BLByrne Lee

Byrne Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Byrne Lee has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Mark Wakabayashi

    Department of Surgery, City of Hope National Medical Center, Duarte, California

    4 shared publications
  • Sinziana Dumitra

    Department of Surgery, City of Hope National Medical Center, Duarte, California

    4 shared publications
  • I. Benjamin Paz

    Department of Surgery, City of Hope National Medical Center , Duarte, California

    3 shared publications
  • Mustafa Raoof

    Department of Surgery, City of Hope National Cancer Center, Medical Office Building, 1500 Duarte Road, Duarte, CA, USA

    3 shared publications
  • Oliver S. Eng

    Department of Surgery, City of Hope National Medical Center , Duarte, California

    3 shared publications
  • Clayton Lau

    Department of Surgery, City of Hope National Cancer Center, Medical Office Building, 1500 Duarte Road, Duarte, CA, USA

    2 shared publications

Latest Publications

  • Open Access

    Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review

    by Eliza W. Beal, Lorena P. Suarez-Kelly, Charles W. Kimbrough, Fabian M. Johnston, Jonathan Greer, Daniel E. Abbott, Courtney Pokrzywa, Mustafa Raoof, Byrne Lee, Travis E. Grotz, et al.

    Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal cancer index score (12.1 + 7.9 vs. 14.3 + 8.5, p = 0.034). There was no significant difference in grade III/IV complications (22.4% vs. 16.7%, p = 0.650), readmission (32.3% vs. 23.5%, p = 0.114), or 30-day mortality (1.5% vs. 2.9%, p = 0.411) between groups. NAC patients experienced longer overall survival (OS) (median 32.7 vs. 22.0 months, p = 0.044) but similar recurrence-free survival (RFS) (median 13.8 vs. 13.0 months, p = 0.456). After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80) or RFS (OR 1.04). Among patients who underwent CRS+/-HIPEC for CR-PM, the use of NAC was associated with improved OS that did not persist on multivariable analysis. However, NAC prior to CRS+/-HIPEC was a safe and feasible strategy for CR-PM, which may aid in the appropriate selection of patients for aggressive cytoreductive surgery.


  • Multivisceral robotic liver surgery: feasible and safe

    by Ioannis T. Konstantinidis, Mustafa Raoof, Vasilena Zheleva, Kelly Lafaro, Clayton Lau, Yuman Fong, Byrne Lee

    The application of robotic technology allows for the performance of multi-organ liver resections by multidisciplinary teams in a minimally invasive manner. Their technique and outcomes are not established. Herein we describe our technique with robotic liver surgery combined with colon, pancreas and urologic resections. Our patients are an 84-year-old (yo) female (Body Mass Index, BMI: 25) with a recently diagnosed right colon adenocarcinoma and two synchronous liver metastases at segments 5 and 6, a 75-year-old female (BMI: 50.4) with a history of right renal cell cancer status post (s/p) right robotic radical nephrectomy now with tumor recurrence with multiple intra-abdominal masses including a segment 7 liver lesion and a 71-year-old female (BMI: 24) with history of pancreatic ductal adenocarcinoma of the tail and a segment 3 liver lesion s/p neoadjuvant chemotherapy. The Xi robotic system (Intuitive Surgical, Sunnyvale, CA, USA) was utilized in all cases. Port placement in all cases was decided within the multidisciplinary teams to accommodate both the hepatic and the extra-hepatic portion of the operation. Parenchymal transections were performed with the use of the Vessel Sealer and the robotic stapler as appropriate. Indocyanine green (ICG) was used to assess the anastomotic perfusion in the first patient. Blood loss was 50 ml for the first two cases and 300 ml for the third. Surgical margins were negative in all cases. Patients were discharged at POD 8, 3 and 5 with one patient experiencing postoperative ileus. Robotic multivisceral liver resections are feasible and safe within multidisciplinary surgical teams with expertise in robotic surgery. The robotic platform can offer a minimally invasive approach in liver surgery synchronous with colonic, pancreatic and urologic surgery.


  • Hypothermia Is Associated with Surgical Site Infection in Cytoreductive Surgery with Hyperthermic Intra-Peritoneal Chemotherapy

    by Oliver S. Eng, Mustafa Raoof, Michael P. O'LEary, Michael W. Lew, Mark T. Wakabayashi, I. Benjamin Paz, Laleh G. Melstrom, Byrne Lee

    Background: Maintenance of peri-operative normothermia remains a global quality metric for hospitals. Hypothermia is associated with surgical site infections (SSIs) in colorectal surgery. Patients undergoing cytoreductive surgery (CRS) with hyperthermic intra-peritoneal chemotherapy (HIPEC) can experience multiple complications post-operatively. We sought to investigate the association of peri-operative hypothermia with SSIs in patients undergoing CRS/HIPEC at our institution. Patients and Methods: Patients undergoing CRS/HIPEC from 2009–2017 were identified retrospectively from a prospectively collected institutional database. Hypothermia defined as less than 36.0°C in accordance with the Agency for Healthcare Research and Quality metric. Regression analyses were performed with SSIs diagnosed within 30 days post-operatively as the primary outcome. Results: A total of 170 patients were identified, 14 (8.2%) of whom developed an SSI. Patients who developed an SSI experienced lower median temperatures (p = 0.027) and a greater percentage of operative time in hypothermia (p = 0.008). On a multivariable analysis adjusting for known risk factors for SSI, the percentage of operative time in hypothermia (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.01–1.07, p = 0.008) was the only parameter associated with SSI within 30 days post-operatively. Conclusion: Hypothermia is associated with the development of SSIs in patients undergoing CRS/HIPEC. Our findings suggest that minimizing peri-operative temperatures to less than 36.0°C may decrease peri-operative SSI in this patient population.


  • Open Access

    Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy

    by Oliver S. Eng, Sinziana Dumitra, Michael O’lEary, Mustafa Raoof, Mark Wakabayashi, Thanh H. Dellinger, Ernest S. Han, Stephen J. Lee, I. Benjamin Paz, Byrne Lee

    Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an important treatment modality for both primary and secondary peritoneal surface cancers. The CRS/HIPEC treatment involves peritonectomy procedures that often are accompanied by visceral organ resections and intestinal anastomoses, followed by perfusion of chemotherapy at 42°C.1,2 Even at high-volume centers, CRS/HIPEC can be associated with major morbidity in greater than 50% of patients across a variety of organ systems.3 This morbidity is multifactorial, as it is affected by patient demographics, tumor biology, and extent of treatment.3,4


  • Robotic Total Pelvic Exenteration: Video-Illustrated Technique

    by Ioannis T. Konstantinidis, William Chu, Federico Tozzi, Clayton Lau, Mark Wakabayashi, Kevin Chan, Byrne Lee

    Robotic-assisted total pelvic exenteration (TPE) can offer a minimally invasive approach to a major multi-organ operation.


  • Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

    by Oliver S. Eng, Sinziana Dumitra, Michael O’lEary, Mark Wakabayashi, Thanh H. Dellinger, Ernest S. Han, Stephen J. Lee, I. Benjamin Paz, Gagandeep Singh, Byrne Lee

    Base excess is important in assessing metabolic status. Postoperative management in patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies can be a challenge, and we therefore sought to investigate perioperative predictors of overall morbidity in CRS/HIPEC patients at our institution.


  • Open Access

    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for sarcomatosis from uterine adenosarcoma

    by Michael P O'LEary, Sinziana Dumitra, Bryan Goldner, Mark Wakabayashi, Byrne Lee

    Uterine adenosarcoma has poor prognosis and management of this disease is controversial. We describe a case of sarcomatosis secondary to recurrent uterine adenosarcoma who underwent cytoreductive surgery (CS) and hyperthermic intraoperative peritoneal chemotherapy (HIPEC). A 52 year-old female presented with perimenopausal menometrorrhagia. She underwent laparoscopic hysterectomy and bilateral salpingo-oopherectomy with pathology showing uterine adenosarcoma. She developed a pelvic recurrence 2 years later. A pelvic exenteration was then performed and within 8 months, she recurred. CS/HIPEC with Cisplatin was performed. Six weeks post-operatively, the patient was found to have recurrence again. This case describes the use of CS/HIPEC as a treatment modality for uterine adenosarcoma with sarcomatosis. Despite CS and HIPEC, the patient developed an aggressive recurrence within six weeks of her surgery date. We recommend a multidisciplinary approach to this disease with the recognition that CS/HIPEC may offer little benefit as a salvage therapy based on this case.


  • Assessment of the Double-Staple Technique for Esophagoenteric Anastomosis in Gastric Cancer

    by Audrey H. Choi, Amanda Arrington, Ann Falor, Rebecca A. Nelson, Michael Lew, Joseph Chao, Byrne Lee, Joseph Kim